1. Home
  2. Nonvalvular Atrial Fibrillation Treatment - NVAF | XARELTO® (rivaroxaban)

XARELTO®: Stroke risk reduction in patients with nonvalvular atrial fibrillation (NVAF)

PROVEN ONCE-DAILY,*
24-HOUR STROKE RISK REDUCTION1,2

*Taken with evening meal.

Demonstrated clinical outcomes in an obesity subgroup population and consistent real-world evidence in patients who have NVAF and morbid obesity3,4

Purple and magenta 24-hour clock icon Proven once-daily,* 24-hour stroke risk reduction1,2 EFFICACY PROFILE
Proven safety profile icon PROVEN SAFETY PROFILE1 SAFETY PROFILE
Magenta and purple N V A F new pill icon ONCE-DAILY DOSING* DOSING
Consistent outcomes in patients with N V A F icon Consistent outcomes
in a subgroup analysis of patients who have NVAF and obesity and in real-world evidence of patients who have NVAF and morbid obesity1,3,4 EXTENSIVE EVIDENCE

◇For VTE prophylaxis in acutely ill medical patients at risk for thromboembolic complications who are not at high risk of bleeding.

   NVAF = nonvalvular atrial fibrillation; VTE = venous thromboembolism.

General Tags: 
NVAF: Reducing stroke risk